Last reviewed · How we verify
NCT06955936
Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
NA trial testing Efferon CT in Myocardial Infarction in 60 participants. Currently enrolling.
29 April 2027
Quick facts
| Lead sponsor | Efferon JSC |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 29 April 2025 |
| Primary completion | 29 April 2027 |
| Estimated completion | 31 July 2027 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Efferon CT
Conditions studied
- Myocardial Infarction — all drugs for Myocardial Infarction →
- Cardiogenic Shock — all drugs for Cardiogenic Shock →
Sponsor
Efferon JSC
Who can join
Adults 18 to 80, any sex, with Myocardial Infarction or Cardiogenic Shock. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction. Cardiogenic shock is a well-known and potent trigger of the immune response, ischemia/reperfusion organ damage, hemolysis and release of free hemoglobin. The activation of immune cells leads to the release of cytokines and inflammatory mediators such as IL-6, IL-8, activated complement and others. As a result of myocardial ischaemia and reperfusion injury, a multiorgan dysfunction syndrome may develop. The Efferon CT hemoadsorption device effectively removes cytokines and other pro-inflammatory molecules (≤55 kDa). This study evaluates whether this blood-filtering therapy can prevent organ failure in acute myocardial infarction patients with cardiogenic shock by eliminating inflammation-inducing mediators.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06955936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Efferon CT
Trials testing the same drug.
- NCT06640114 — Hemoperfusion With Efferon CT for the Treatment of Patients With Severe Psoriasis · NA · completed
- NCT05694988 — Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis · NA · recruiting
- NCT06404424 — Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock · completed
- NCT05695001 — Hemoperfusion Efferon СT for the Treatment of Patients With Acute Pancreatitis · completed
- NCT05104398 — Hemoperfusion With the Efferon CT Extracorporeal Adsorbers in Patients With Severe Covid-19 · completed
Other recruiting trials for Myocardial Infarction
Currently open trials in the same condition.
- NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
- NCT07402642 — Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome · NA · recruiting
- NCT07301034 — A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, · Phase 3 · recruiting
- NCT07142265 — Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients · recruiting
- NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting
Other Efferon JSC trials
Trials by the same sponsor.
- NCT07532174 — Efferon LPS Hemoadsorption in Cardiac Surgery Patients · NA · recruiting
- NCT07267169 — Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis · NA · recruiting
- NCT07383597 — Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease · NA · not yet recruiting
- NCT07259668 — Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Thermal Burns · recruiting
- NCT07248930 — Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Thermal Burns · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06955936 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Efferon JSC
- Last refreshed: 5 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06955936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing